COUR Pharmaceuticals

COUR Pharmaceuticals is pioneering a novel approach to treating autoimmune diseases by addressing their root cause: the immune system's loss of self-tolerance. The company's proprietary COUR Nanoparticle Platform (CNP) delivers specific antigens to antigen-presenting cells in the liver and spleen, inducing durable, antigen-specific immune tolerance. With a diverse pipeline in development and in-house manufacturing capabilities, COUR aims to transform the standard of care for a wide range of immune-mediated conditions, moving beyond symptomatic relief to potentially disease-modifying therapies.

COUR Nanoparticle Platform (CNP): A first-in-class, antigen-specific immune tolerance technology using biodegradable, negatively charged nanoparticles (~500 nm) to deliver disease-specific antigens to antigen-presenting cells in the liver/spleen, reprogramming pathogenic T-cells and inducing durable immune tolerance.

COUR competes with large pharma and biotech companies developing immunosuppressive biologics (e.g., anti-TNFs, IL inhibitors) and newer modalities like CAR-Tregs or other antigen-specific therapies. Its key differentiation is a potentially durable, off-the-shelf, antigen-specific tolerance platform with a low treatment burden, aiming for disease modification rather than chronic symptom management.